3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
2
Rectal Neoplasms
2
Neoplasms
2
Stomach Neoplasms
1
Post-operative Ileus
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Polyps
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Advanced Gastric Carcinoma
1
Interventions
pembrolizumab
37
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
enfortumab vedotin
10
Carboplatin
10
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
Defecation
×
Clear all
NCT04970472
2026-03-19
MicroBlad
University Hospital, Toulouse
Recruiting
1,000 enrolled